Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068332 | 1.00 | MTNR1A (0.60) | MTNR1AEPHX2MEN1KMT2ATRPV1 | |
| SCHEMBL1064566 | 0.95 | MTNR1A (0.58) | MTNR1AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20648045 | 0.88 | KMT2A (0.65) | MTNR1AMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL1082713 | 0.80 | SIGMAR1 (0.49) | OXER1 | |
| SCHEMBL3667836 | 0.79 | MEN1 (0.52) | MTNR1AMEN1KMT2A | |
| SCHEMBL13973212 | 0.79 | KMT2A (0.59) | MEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL12017348 | 0.77 | MEN1 (0.46) | MTNR1AMEN1KMT2A | |
| SCHEMBL17943476 | 0.77 | POLB (0.58) | MTNR1AMEN1KMT2A | |
| SCHEMBL22411433 | 0.75 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1 | |
| SCHEMBL1727281 | 0.75 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872040-B2 | Receptor blocker and vasodilator comprising indole derivative as active ingredient | SOMEI MASANORI | 2011-01-18 | — | — | US | disclosed |
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | ADRB2, ADRB1, ADRA2B | MTNR1A 261/4885EPHX2 2985/4885MEN1 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.